Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J H Schulte

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Acta Crystallographica. Section C, Crystal Structure Communications|November 14, 2001
A monomeric three-coordinate magnesium bis(amide)A R Kennedy, R E Mulvey, J H Schulte
Oncogene|April 14, 2009
Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressivenessF Cimmino, J H Schulte, M Zollo, et al.
Klinische Padiatrie|December 17, 2003
Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapyJ H Schulte, A Schramm, T Pressel, et al.
Klinische Padiatrie|October 30, 2013
Targeted Therapy for Neuroblastoma: ALK InhibitorsJ H Schulte, S Schulte, L C Heukamp, et al.
Oncogene|April 10, 2012
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cellsJ H Schulte, S Lindner, A Bohrer, et al.
Oncogene|December 1, 2009
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumorsP Mestdagh, E Fredlund, F Pattyn, et al.
The Journal of Pathology|October 16, 2008
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcomaN Friedrichs, J Küchler, E Endl, et al.
British Journal of Cancer|October 11, 2012
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcomeA Schramm, B Schowe, K Fielitz, et al.
Oncogene|September 2, 2014
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studiesK Althoff, A Beckers, E Bell, et al.
Oncogene|August 24, 2011
Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastomaE E Santo, M E Ebus, J Koster, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Acta Crystallographica. Section C, Crystal Structure Communications|November 14, 2001
A monomeric three-coordinate magnesium bis(amide)A R Kennedy, R E Mulvey, J H Schulte
Oncogene|April 14, 2009
Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressivenessF Cimmino, J H Schulte, M Zollo, et al.
Klinische Padiatrie|December 17, 2003
Microarray-analysis: a new approach to study the molecular mechanisms of thermo-chemotherapyJ H Schulte, A Schramm, T Pressel, et al.
Klinische Padiatrie|October 30, 2013
Targeted Therapy for Neuroblastoma: ALK InhibitorsJ H Schulte, S Schulte, L C Heukamp, et al.
Oncogene|April 10, 2012
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cellsJ H Schulte, S Lindner, A Bohrer, et al.
Oncogene|December 1, 2009
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumorsP Mestdagh, E Fredlund, F Pattyn, et al.
The Journal of Pathology|October 16, 2008
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcomaN Friedrichs, J Küchler, E Endl, et al.
British Journal of Cancer|October 11, 2012
Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcomeA Schramm, B Schowe, K Fielitz, et al.
Oncogene|September 2, 2014
A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studiesK Althoff, A Beckers, E Bell, et al.
Oncogene|August 24, 2011
Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastomaE E Santo, M E Ebus, J Koster, et al.
Pageof 2